Study of exceptional responders with solid tumors on chemotherapy
Part of Cancer clinical trials.
This study looks at people with solid tumor cancer (like many common carcinomas) to understand who responds exceptionally well to chemotherapy. You might be eligible if you are newly diagnosed or already receiving chemotherapy and can follow the study plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor cancer diagnosis (carcinoma) from a lab test on tissue or body fluid.
- You are not yet treated for cancer, or you are currently receiving chemotherapy.
- Your overall functioning is acceptable for the study (no major limits expected).
- If you have HIV, you must not be taking anti-HIV medicines (antiretroviral therapy).
- You cannot be pregnant or nursing.
- You must not have had an organ transplant in the past and must be able to follow the study plan without a condition that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.
This study tests an experimental drug called EP0089 for people with advanced solid tumors that haven't responded to other treatments. It aims to find a safe dose and see if it helps control the cancer.
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
This study collects and analyzes tumor samples from people with advanced solid cancers to understand why some treatments work better than others and why resistance can develop. It aims to improve future treatments for patients like you.
Hear when a new Solid Tumor Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.